EU regulators agree to review LEO’s dermatitis drug
The drug targets a key driver of the underlying inflammation in the condition
Read More
Tag: tralokinumab
AZ’ experimental asthma drug fails in Phase III
An experimental therapy being developed by AstraZeneca and its biologics research and development arm MedImmune has failed to hit key targets in two Phase III trials.
Read More
Setback for AZ’ asthma drug as trial misses endpoint
AstraZeneca’s tralokinumab has failed to significantly reduce the rate of annual exacerbations in patients with uncontrolled asthma taking part in a late-stage trial.
Read More
NIHR partners with AstraZeneca on asthma study
The National Institute for Health Research and AstraZeneca have formed a new partnership aiming to progress “crucial research” in respiratory disease.
Read More
LEO buys rights to AstraZeneca’s skin drug
LEO Pharma has entered a strategic partnership with AstraZeneca for new medicines for atopic dermatitis and psoriasis, major skin diseases with a significant unmet medical need.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
